Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives $26.50 Average PT from Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have earned a consensus recommendation of “Reduce” from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $26.50.

Several analysts recently issued reports on the company. Citigroup cut their target price on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a research report on Tuesday, October 1st. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America decreased their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. JMP Securities decreased their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Finally, Truist Financial decreased their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th.

Integra LifeSciences Trading Up 0.6 %

NASDAQ IART opened at $19.87 on Friday. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The stock has a market cap of $1.57 billion, a P/E ratio of 39.74, a P/E/G ratio of 0.62 and a beta of 1.09. The stock’s fifty day moving average price is $19.03 and its 200-day moving average price is $25.51. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The firm had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. During the same period in the prior year, the company posted $0.71 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. As a group, equities analysts forecast that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Several institutional investors have recently made changes to their positions in IART. Blue Trust Inc. increased its position in shares of Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 444 shares during the period. CWM LLC boosted its stake in shares of Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after buying an additional 425 shares during the period. Valley National Advisers Inc. acquired a new stake in shares of Integra LifeSciences during the first quarter worth about $63,000. Canada Pension Plan Investment Board acquired a new stake in shares of Integra LifeSciences during the second quarter worth about $114,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in Integra LifeSciences by 58.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock worth $136,000 after purchasing an additional 1,711 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.